Navigation Links
Boehringer Ingelheim Comments on June 18th FDA Advisory Committee Meeting
Date:6/18/2010

RIDGEFIELD, Conn., June 18 /PRNewswire/ -- The Reproductive Health Drugs Advisory Committee met today to discuss the new drug application (NDA) for flibanserin 100 mg as a treatment for Hypoactive Sexual Desire Disorder (HSDD) in pre-menopausal women.  The advisory committee was convened by and makes recommendations to the U.S. Food and Drug Administration (FDA).  The FDA will consider the committee's advice as part of its final assessment of the NDA.  

The committee recognized the significant unmet medical need for women with HSDD and the lack of approved treatments for this condition.  Members of the committee advised that additional data are necessary to further support the efficacy and safety profile of flibanserin and recommended that clinical development of the drug continue.

"We are disappointed with the advisory committee's recommendations and will work with the FDA to address questions raised by the advisory committee," said Christopher Corsico, M.D., M.P.H., U.S. medical director, Boehringer Ingelheim Pharmaceuticals, Inc.  "Our ongoing flibanserin clinical trial program demonstrates our continued commitment to women with HSDD."


'/>"/>
SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Boehringer Ingelheim Receives Top Honor as Worlds Most Respected Biopharmaceutical Employer in Science 2007 Top Employers Survey
2. Dalton Medicinal Chemistry Partners Achieves Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
3. Astellas and Boehringer Ingelheim Reach Settlement Agreement with Ranbaxy on Flomax Patent Case
4. Dalton Medicinal Chemistry Partners Achieves Another Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
5. Boehringer Ingelheim Pharmaceuticals, Inc. Receives the NCQA Seal Of Approval
6. More Than Half of Patients Treated for Benign Prostatic Hyperplasia Receive Boehringer Ingelheims Flomax as First-Line Therapy
7. Boehringer Ingelheim and BioSpace Search for Scientists at Career Fair in Boston, Massachusetts
8. Rentschler Biotechnologie Announces Cooperation with Boehringer Ingelheim
9. Ingenuity Systems Announces Multi-Year Agreement With Boehringer Ingelheim
10. Boehringer Ingelheim and Micromet Announce Global Collaboration for Multiple Myeloma BiTE Antibody
11. Former Banc of America Securities Analyst David Maris Comments on Decision by Biovail to Drop Its Claims Against Him; Denies That He is Cooperating With Biovail
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , September 2, 2015 ... primär auf die Forschung und Entwicklung neuartiger ... Allergien, chronisch-entzündliche Darmerkrankungen und Reizdarm konzentriert, erhält ... Zusage, dass sein neues Medikament patentiert wird. ... das Allergien bei Kindern verhindert und Entzündungen ...
(Date:9/1/2015)... 1, 2015  ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ... commercialization of targeted antiviral therapies, announced today that it ... Annual Global Investment Conference sponsored by H.C. ... at The St. Regis Hotel in New ... Sapirstein , Chief Executive Officer, will provide an overview ...
(Date:9/1/2015)... ... 01, 2015 , ... In her thought provoking debut novel ‘ Ebola Vaccine ... future faced with an Ebola pandemic that is on the cusp of wiping out ... the world of counterterrorism, and who continues to appear in this series of books ...
(Date:9/1/2015)... 1, 2015 The Dohmen Company today ... Ph.D., MBA as Chief Science Officer (CSO) of ... created role, Dr. Floyd will lead Dohmen,s growing ... of pre-commercial and post approval outsourced services in ... communications.  Dr. Floyd brings decades of experience leading ...
Breaking Biology Technology:Das Patent von Swecure zur Verhinderung von Allergien bei Kindern wird in den USA zugelassen 2ContraVir to Present at Rodman & Renshaw 17th Annual Global Investment Conference 2Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 2Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 3Dohmen Life Science Services Appoints Eric Floyd, Ph.D. as Chief Science Officer 2Dohmen Life Science Services Appoints Eric Floyd, Ph.D. as Chief Science Officer 3
(Date:8/6/2015)... and TELTOW, Germany , ... 2015 Siggraph Conference, SensoMotoric Instruments (SMI) shows ... reality , based on Epson,s Moverio BT-200 ... tracking platform. With this new solution, unprecedented quality and ... hands-free interaction with context-sensitive displays. For the first time, ...
(Date:8/5/2015)... August 5, 2015 Transparency Market ... Recognition Market - Global Industry Analysis, Size, Share, Growth, ... for facial recognition is forecast to reach US$ 2,671.8 ... demand for surveillance systems by civil and government agencies. ... crimes and terrorist activities across the globe that would ...
(Date:8/4/2015)... 2015  AMRI (NASDAQ: AMRI ) today reported financial and ... Highlights: , Second quarter contract revenue of ... , Adjusted contract margins of 26 % ... a $0.05 decrease in EPS from royalties in the current quarter ... "We are very pleased to present another strong financial ...
Breaking Biology News(10 mins):SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24
... Mass. Though the human genome has been sequenced, scientists ... help people, for example, how it can be used to ... notes, "It was easy to think of the human genome ... it,s just a foot in the door." "What we,re ...
... April 30, 2012 -- Autism has a strong genetic basis, ... had mixed results. The reason for this is that autism ... involved in different individuals, making it hard to find the ... the Hebrew University of Jerusalem has shown that despite this ...
... out another old wives, tale: Sleeping too much does not make ... sleep and body mass index (BMI) in twins, which found that ... influences on body weight. The study looked at 1,088 ... a night was associated with both increased BMI and greater genetic ...
Cached Biology News:Geneticist develops tool to identify genes important in disease, tailoring individual treatment 2Geneticist develops tool to identify genes important in disease, tailoring individual treatment 3Researchers at Hebrew University identify genetic systems disrupted in autistic brain 2
The Bio-Plex Manager version 3.0 to 4.0 workstation software upgrade kit is used to upgrade existing Bio-Plex Manager version 3.0 software to version 4.0 security edition software....
... --- a cocktail of 3 siRNAs specifically ... our most popular product. The siTrio reagent ... of your target gene when used under ... and confirmation of optimal transfection with one ...
... is a competitive enzymeimmunoassay (EIA) for the ... rat serum or plasma. Corticosterone is the ... and mice, and in most non-mammalian vertebrates ... mammals produce both corticosterone and cortisol, in ...
... is a molecular screening, low melting point ... sieving. It is recommended for separation of ... such as PCR products. Micro ABgarose is ... not recommended for blotting techniques. At a ...
Biology Products: